Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Islatravir in Moderate Hepatic Impairment
NCT04515641Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve From Time 0 to Infinity at 168 hours and Maximum Concentration at 168 hours. Started Nov 2020; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04515641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515641.